Idelalisib and CLL
A phase III trial examining the use of idelalisib in patients with chronic lymphocytic leukaemia (CLL) will be stopped early as an interim analysis demonstrated significant improvement in progression-free survival, the primary end point.
The trial, known as Study 116, compares idelalisib plus rituximab with rituximab alone in patients with previously treated recurrent CLL. Patients also had measurable lymphadenopathy with disease progression less than 24 months following completion of prior therapy and needed treatment but were unsuitable for conventional chemotherapy. Patients in the treatment arm will continue to receive idelalisib while those in the control arm will be eligible to receive idelalisib in an extension study. For more information, click here.